Health
CVS to Replace AbbVie’s Blockbuster Humira With Cheaper Rivals
- Caremark is first major PBM to shift from blockbuster drug
- Patients will be moved to copycat versions starting April 1
AbbVie’s sales of Humira topped $21 billion in 2022.
Photographer: JB Reed/Bloomberg
This article is for subscribers only.
The biggest US drug-benefits manager is making a move that will take a bite out of sales for one of the world’s top-selling medications.
Starting April 1, CVS Health Corp. will no longer offer AbbVie Inc.’s Humira to most of the millions of patients in its commercial prescription plans. Instead, they’ll be directed to cheaper copycats of the anti-inflammatory drug that became available last year.